SQUAWK/NEWS
Account
Account
Menu
Live News EQUITY FLASH M impact

AVIR Completes Enrollment

Atea Pharmaceuticals completes patient enrollment in Phase 3 C-FORWARD trial for Hepatitis C treatment

AVIR

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.